Related Experiment Video
Updated: Jun 14, 2026

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
Published on: June 6, 2025
Hypertension and common complications --analysis of the ambulatory treatment cost
Anna D Ivanova1, Guenka I Petrova
1Department of Social Pharmacy, Faculty of Pharmacy, Medical University, Sofia, Bulgaria. an5dar@yahoo.co.uk
Insights
This study analyzed hypertension treatment costs in Bulgaria, finding that complications significantly increase patient expenses. Medicine prices, not therapy complexity, most impact overall ambulatory hypertension care costs.
Area of Science:
- Cardiovascular Medicine
- Health Economics
- Pharmacoeconomics
Background:
- Hypertension and its complications (heart failure, cerebrovascular disease sequelae, angina pectoris) represent a significant public health burden.
- Understanding prescribing patterns and associated costs in ambulatory care is crucial for effective healthcare management.
Purpose of the Study:
- To retrospectively analyze prescribing practices and costs for ambulatory hypertension treatment and its common complications.
- To model and calculate the expected monthly and annual costs of outpatient therapy for hypertension and its complications.
- To assess the sensitivity of therapy costs to medicine prices and treatment complexity.
Main Methods:
- Retrospective analysis of 3,240 reimbursable ambulatory prescriptions for hypertension and its complications.
- Categorization of prescriptions by therapy complexity and medicine frequency.
- Utilized a decision tree model for cost calculation and performed sensitivity analysis (+/- 30%).
Main Results:
- Hypertension prescriptions accounted for 65% of the total, with 35% for complications.
- Most hypertension prescriptions (67%) involved one or two medications; only 8% used three.
- ACE inhibitors were most common (41%) for hypertension; complication therapies were more diverse. Expected monthly costs were €6.90 for hypertension alone and €10.71 with complications.
- Overall annual ambulatory cost estimated at €148 million for 1.5 million patients (44% reimbursement). Therapy cost sensitivity was higher to medicine prices than complexity.
Conclusions:
- This study provides initial data for evidence-based cost containment strategies in Bulgarian ambulatory care.
- It highlights the significant contribution of complication therapy to the overall cost of hypertension management.
- Findings can inform policy decisions regarding hypertension treatment and resource allocation.
Aim:
Retrospective analysis of the prescribing practice and cost of ambulatory treatment of hypertension and its common complications--heart failure, sequelae of cerebrovascular disease, and angina pectoris.
Methods:
Analysis of 3,240 reimbursable ambulatory prescriptions for hypertension, heart failure, sequelae of cerebrovascular disease and angina pectoris according to the complexity of the therapy and frequency of the prescribed medicines. Modeling and calculation of the expected monthly cost for outpatient therapy by using the "decision tree model". Sensitivity analysis is performed within the +/- 30% interval.
Results:
65% of the prescription were for the hypertension, and 35% for the observed complications. 1,297 prescriptions for hypertension include one medicine, 647 include two medicines, and only 8% of prescriptions were for three medicines. ACE inhibitors have been prescribed in 41% of all hypertension prescriptions, followed by beta-blockers (19%), Ca channel blockers (16%), diuretics (15%) etc. The prescriptions for hypertension complications are more diverse as therapeutic groups. The expected monthly cost of prescribed medicines per patient with hypertension alone is 6.90 Euro and in case of complications it is 10.71 Euro according to the prevalence of the complexity of therapy, and weighted monthly cost of medicines. The overall ambulatory cost is expected to be around 148 million Euro per year for near 1.5 million patients with 44% reimbursement. The cost of the therapy is sensitive more to changes in the medicine's prices than to its complexity.
Conclusion:
This study is a first step in providing information for evidence-based cost containment measures or policy decisions at ambulatory level in Bulgaria and for the assessment of the share of complications' therapy on the overall hypertension cost.
Related Concept Videos
Hypertension III: Clinical Manifestations and Diagnostic Studies
Hypertension V: Nursing Management
Errors occurring during blood pressure monitoring
Several factors...
Hypertension and Regulation of Blood Pressure
Hypertension I: Introduction
Hypertension IV: Drug Therapy and Lifestyle Modifications